Acadia Pharma Soars After FDA Investigation Clears Nuplazid of Additional Safety Problems

Shares of Acadia Pharmaceuticals soared more than 26 percent in trading on Thursday and continue to climb this morning in premarket trading after the U.S. Food and Drug Administration affirmed the safety profile of the company’s lead drug, Nuplazid.